Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
– CABINET trial will be unblinded and stopped early due to a dramatic improvement in efficacy per a unanimous recommendation by The Alliance for Clinical Trials in Oncology independent Data and...
Jennifer Chan Program In Carcinoid Exchange Commission National Clinical Trials Network National Cancer Institute Cancer Therapy Evaluation Program
Source: marketscreener.com